Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis
Abstract
Purpose:
Erythrocytosis is the most common dose limiting adverse effect of testosterone therapy but the mechanisms of testosterone mediated erythropoiesis remain unclear. In this study we examine risk factors for erythrocytosis associated with testosterone therapy.
Materials and Methods:
A retrospective review was performed of 179 hypogonadal men on testosterone therapy at a single andrology clinic. Demographic data, testosterone therapy formulation and duration of treatment, and 5α-reductase inhibitor use were assessed. Serum dihydrotestosterone, total testosterone, free testosterone, follicle-stimulating hormone, luteinizing hormone, hematocrit and lipid levels were extracted, and changes during treatment were determined. Spearman’s rank correlation was used to identify relationships between change in hematocrit and study variables.
Results:
Of 179 patients 49 (27%) experienced a 10% or greater change in hematocrit and erythrocytosis (hematocrit 50% or greater) developed in 36 (20.1%) at a median followup of 7 months. Topical gels were used by 41.3% of patients, injectable testosterone by 52.5% and subcutaneous pellets by 6.1%. More men who experienced a change in hematocrit of 10% or greater used injectable testosterone than men with a change in hematocrit of less than 10% (65% vs 48%, p=0.035), and were less likely to be on a 5α-reductase inhibitor (2% vs 15%, p=0.017). Men with a change in hematocrit of 10% or greater had higher posttreatment dihydrotestosterone levels (605.0 vs 436.0 ng/dl, p=0.017) and lower luteinizing hormone and follicle-stimulating hormone levels than men with a change in hematocrit of less than 10%. Spearman’s rank correlations yielded relationships between change in hematocrit and posttreatment dihydrotestosterone ρ=0.258, p=0.001) and total testosterone (ρ=0.171, p=0.023).
Conclusions:
Dihydrotestosterone may have a role in testosterone therapy related erythrocytosis and monitoring dihydrotestosterone levels during testosterone therapy should be considered. In men in whom erythrocytosis develops, 5α-reductase inhibitors may be therapeutic.
References
- 1 : Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med2004; 350: 482. Google Scholar
- 2 : The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag2009; 5: 427. Google Scholar
- 3 : Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci2005; 60: 1451. Google Scholar
- 4 : ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res2009; 21: 1. Google Scholar
- 5 : Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab2008; 93: 914. Google Scholar
- 6 : Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab2010; 95: 2560. Google Scholar
- 7 : Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc2007; 82: 29. Google Scholar
- 8 : Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol2001; 110: 237. Google Scholar
- 9 : Hypogonadism in the aging male: diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol2011; 1: 2012. Google Scholar
- 10 : Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Eur J Endocrinol2010; 162: 385. Google Scholar
- 11 : Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab1997; 82: 1661. Google Scholar
- 12 : Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab1999; 84: 3469. Google Scholar
- 13 : Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab2010; 95: 4743. Google Scholar
- 14 : Association of cigarette smoking, alcohol consumption, and physical activity with sex steroid hormone levels in US men. Cancer Causes Control2009; 20: 877. Google Scholar
- 15 : Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab2007; 92: 3844. Google Scholar
- 16 : The diagnosis and management of erythrocytosis. BMJ2013; 347: f6667. Google Scholar
- 17 : Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci2014; 69: 725. Google Scholar
- 18 : Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Ann Intern Med2010; 153: 621. Google Scholar
- 19 : A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab2001; 86: 4078. Google Scholar
- 20 : Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol2013; 190: 639. Link, Google Scholar
- 21 : Effects of testosterone replacement therapy on hepcidin levels in young hypogonadal men. Endocr Abstracts2013; 32: 659. Google Scholar
- 22 : Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab2004; 89: 503. Google Scholar
- 23 : The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab2002; 87: 1467. Google Scholar
- 24 : Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab2005; 90: 1502. Google Scholar
- 25 : Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA2012; 307: 931. Google Scholar
- 26 : The role of 5α-reductase inhibition in men receiving testosterone replacement therapy. JAMA2012; 307: 968. Google Scholar
- 27 : More than eight years’ hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl2007; 9: 291. Google Scholar
- 28 : Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism. J Androl2012; 33: 420. Google Scholar
